Miensheng Chu1, Stefanie Mares Novak1, Cathleen Cover1, Anne A Wang1, Ikeotunye Royal Chinyere2, Elizabeth B Juneman2, Daniela C Zarnescu3, Pak Kin Wong4, Carol C Gregorio5. 1. Department of Cellular and Molecular Medicine and Sarver Molecular Cardiovascular Research Program (M.C., S.M.N., C.C., A.A.W., C.C.G.). 2. Department of Medicine (I.R.C., E.B.J.). 3. Department of Molecular and Cellular Biology (D.C.Z.). 4. University of Arizona, Tucson. Department of Biomedical Engineering at Pennsylvania State University, University Park (P.K.W.). 5. Department of Cellular and Molecular Medicine and Sarver Molecular Cardiovascular Research Program (M.C., S.M.N., C.C., A.A.W., C.C.G.) gregorio@email.arizona.edu.
Abstract
BACKGROUND: Gap junction remodeling is well established as a consistent feature of human heart disease involving spontaneous ventricular arrhythmia. The mechanisms responsible for gap junction remodeling that include alterations in the distribution of, and protein expression within, gap junctions are still debated. Studies reveal that multiple transcriptional and posttranscriptional regulatory pathways are triggered in response to cardiac disease, such as those involving RNA-binding proteins. The expression levels of FXR1 (fragile X mental retardation autosomal homolog 1), an RNA-binding protein, are critical to maintain proper cardiac muscle function; however, the connection between FXR1 and disease is not clear. METHODS: To identify the mechanisms regulating gap junction remodeling in cardiac disease, we sought to identify the functional properties of FXR1 expression, direct targets of FXR1 in human left ventricle dilated cardiomyopathy (DCM) biopsy samples and mouse models of DCM through BioID proximity assay and RNA immunoprecipitation, how FXR1 regulates its targets through RNA stability and luciferase assays, and functional consequences of altering the levels of this important RNA-binding protein through the analysis of cardiac-specific FXR1 knockout mice and mice injected with 3xMyc-FXR1 adeno-associated virus. RESULTS: FXR1 expression is significantly increased in tissue samples from human and mouse models of DCM via Western blot analysis. FXR1 associates with intercalated discs, and integral gap junction proteins Cx43 (connexin 43), Cx45 (connexin 45), and ZO-1 (zonula occludens-1) were identified as novel mRNA targets of FXR1 by using a BioID proximity assay and RNA immunoprecipitation. Our findings show that FXR1 is a multifunctional protein involved in translational regulation and stabilization of its mRNA targets in heart muscle. In addition, introduction of 3xMyc-FXR1 via adeno-associated virus into mice leads to the redistribution of gap junctions and promotes ventricular tachycardia, showing the functional significance of FXR1 upregulation observed in DCM. CONCLUSIONS: In DCM, increased FXR1 expression appears to play an important role in disease progression by regulating gap junction remodeling. Together this study provides a novel function of FXR1, namely, that it directly regulates major gap junction components, contributing to proper cell-cell communication in the heart.
BACKGROUND: Gap junction remodeling is well established as a consistent feature of humanheart disease involving spontaneous ventricular arrhythmia. The mechanisms responsible for gap junction remodeling that include alterations in the distribution of, and protein expression within, gap junctions are still debated. Studies reveal that multiple transcriptional and posttranscriptional regulatory pathways are triggered in response to cardiac disease, such as those involving RNA-binding proteins. The expression levels of FXR1 (fragile X mental retardation autosomal homolog 1), an RNA-binding protein, are critical to maintain proper cardiac muscle function; however, the connection between FXR1 and disease is not clear. METHODS: To identify the mechanisms regulating gap junction remodeling in cardiac disease, we sought to identify the functional properties of FXR1 expression, direct targets of FXR1 in human left ventricle dilated cardiomyopathy (DCM) biopsy samples and mouse models of DCM through BioID proximity assay and RNA immunoprecipitation, how FXR1 regulates its targets through RNA stability and luciferase assays, and functional consequences of altering the levels of this important RNA-binding protein through the analysis of cardiac-specific FXR1 knockout mice and mice injected with 3xMyc-FXR1 adeno-associated virus. RESULTS:FXR1 expression is significantly increased in tissue samples from human and mouse models of DCM via Western blot analysis. FXR1 associates with intercalated discs, and integral gap junction proteins Cx43 (connexin 43), Cx45 (connexin 45), and ZO-1 (zonula occludens-1) were identified as novel mRNA targets of FXR1 by using a BioID proximity assay and RNA immunoprecipitation. Our findings show that FXR1 is a multifunctional protein involved in translational regulation and stabilization of its mRNA targets in heart muscle. In addition, introduction of 3xMyc-FXR1 via adeno-associated virus into mice leads to the redistribution of gap junctions and promotes ventricular tachycardia, showing the functional significance of FXR1 upregulation observed in DCM. CONCLUSIONS: In DCM, increased FXR1 expression appears to play an important role in disease progression by regulating gap junction remodeling. Together this study provides a novel function of FXR1, namely, that it directly regulates major gap junction components, contributing to proper cell-cell communication in the heart.
Authors: Lan Lan; Carl Appelman; Amber R Smith; Jia Yu; Sarah Larsen; Rebecca T Marquez; Hao Liu; Xiaoqing Wu; Philip Gao; Anuradha Roy; Asokan Anbanandam; Ragul Gowthaman; John Karanicolas; Roberto N De Guzman; Steven Rogers; Jeffrey Aubé; Min Ji; Robert S Cohen; Kristi L Neufeld; Liang Xu Journal: Mol Oncol Date: 2015-04-10 Impact factor: 6.603
Authors: Sandra Van't Padje; Bill Chaudhry; Lies-Anne Severijnen; Herma C van der Linde; Edwin J Mientjes; Ben A Oostra; Rob Willemsen Journal: J Exp Biol Date: 2009-08 Impact factor: 3.312
Authors: Edwin J Mientjes; Rob Willemsen; Laura L Kirkpatrick; Ingeborg M Nieuwenhuizen; Marianne Hoogeveen-Westerveld; Marcel Verweij; Surya Reis; Barbara Bardoni; Andre T Hoogeveen; Ben A Oostra; David L Nelson Journal: Hum Mol Genet Date: 2004-05-05 Impact factor: 6.150
Authors: Christopher A Koczor; Eva K Lee; Rebecca A Torres; Amy Boyd; J David Vega; Karan Uppal; Fan Yuan; Earl J Fields; Allen M Samarel; William Lewis Journal: Physiol Genomics Date: 2013-05-21 Impact factor: 3.107
Authors: Jian-Fu Chen; Elizabeth P Murchison; Ruhang Tang; Thomas E Callis; Mariko Tatsuguchi; Zhongliang Deng; Mauricio Rojas; Scott M Hammond; Michael D Schneider; Craig H Selzman; Gerhard Meissner; Cam Patterson; Gregory J Hannon; Da-Zhi Wang Journal: Proc Natl Acad Sci U S A Date: 2008-02-06 Impact factor: 11.205